Indivumed Therapeutics’ Post

Take a look in our recent paper about molecular profiling of bladder cancer! #beyondgenomics

I'm very happy to announce the publication of our latest book chapter titled: "Chemotactic Signaling Pathways in Prostate Cancer: Implications in the Tumor Microenvironment and as Potential Therapeutic Targets", recently published in the International Review of Cell and Molecular Biology (Book Series) journal 📚. It has been a pleasure collaborating on this project alongside my mentor and colleague, Dr. Eva Martínez Balibrea, and Dr. Zoila Areli Lopez-Bujanda. 💡This chapter delves into how chemotactic signaling influences the tumor microenvironment and its crucial role in immune evasion and cancer progression. We also explore the rationale behind targeting these pathways directly or indirectly as adjuvant therapies for metastatic castration-resistant prostate cancer , shedding light on recent pre-clinical and clinical studies currently underway. Germans Trias i Pujol Research Institute (IGTP), Catalan Institute of Oncology #ProstateCancer #CancerResearch #TherapeuticTargets #Chemokines #TumorMicroenvironment https://lnkd.in/d8asD2Wf

#Circulating tumor #DNA (ctDNA) testing represents a significant advancement in precision oncology. ctDNA refers to small fragments of tumor-derived DNA that are released into the bloodstream as #cancer cells die and disintegrate. Unlike traditional #tissue biopsies, which involve invasive procedures to extract tumor tissue, CtDNA #testing uses a simple blood sample—often termed a "liquid biopsy"—to analyze these fragments. #G2M CtDNA Lung #Panel screens lung cancer causing genes to identify somatic #mutations in DNA from #blood tissue. It provides comprehensive detail of the cancer and helps to decide the best course of #treatment. The screening method involves using circulating tumor cells that are used as biomarkers to detect lung cancer. Circulating tumor DNA (ctDNA) is released from apoptotic and #necrotic tumor cells. #Applications of ctDNA in lung cancer include early #diagnosis and detection, prognosis prediction, detecting mutations and #structural alterations, minimal residual #disease, tumor mutational burden, and tumor evolution tracking. Visit our website for more information: https://lnkd.in/dWk-ahgF #lungcancer #cancerpanel #cell #genes2me #diagnosis #awareness #worldlungday #lungday #worldlungday2024 #lungday2024

Exciting news for Breast Cancer Awareness Month! Dr Alessandra Virga and Prof sara bravaccini from the IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST Srl latest publication with Plasma-SeqSensei is out! The Novel AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 Inhibitors is now available!  The study used Sysmex’s Plasma-SeqSensei Breast Cancer IVD to assess the biomarkers from 16 HR /HER2-negative breast cancer patients. The team then monitored the patients at baseline (T0) and again 3 months (T1) into treatment. Here's a sneak peek of what they discovered: Takeaway: Alterations in PIK3CA are linked to poorer PFS, aligning with recent findings in the field. Plasma-SeqSensei detected mutations in key genes, including ESR1, down to a sensitivity of 0.06%. Conclusion: Plasma-SeqSensei is easy to use and highly accurate, detecting gene alterations as low as 0.06% MAF—an essential tool for precision oncology in HR /HER2-negative breast cancer.  👉 https://lnkd.in/ezBgr-hi #Sysmex #BreastCancer

Exciting News!! 🔬 We are thrilled to share this new publication citing the use of Luminicell products in cutting-edge research on prostate cancer bone metastasis! 🔍 The study utilized Luminicell Tracker 670 for labelling circulating cancer cells in an engineered bone tissue model. This allowed researchers to track the intravasation of cancer cells within bone tissues over a 4-week period using the IVIS Spectrum Optical Imaging System. 💡 The fluorescence of labeled cancer cells within the bone tissues was quantified, providing valuable insights into the dynamics of bone metastasis. 🌟 Our team is happy to be enabling researchers to unravel the complexities of cancer metastasis and advance targeted therapeutic strategies. Stay tuned for more updates as we continue to empower cutting-edge research in the fight against cancer! 📚 Read the full article here: https://lnkd.in/gUdZ_uRt Thinking to illuminate your research? Check out our cell labelling kits here: https://lnkd.in/gsTnufs9 Arriaga, J.M., Ronaldson-Bouchard, K., Picech, F. et al. In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis. Oncogene(2024). #CancerResearch #Bioimaging #Luminicell #ProstateCancer #Metastasis #Innovation #CRISP #organonachip #IVIS

Revolutionizing Cancer Treatment (Gastrointestinal Tumors) 🚀 A landmark study published in Nature Medicine on 16 September 2024 has unveiled a groundbreaking approach to treating advanced gastrointestinal tumors through targeted therapy using circulating tumor DNA (ctDNA) analysis. This innovative technique offers a more personalized treatment strategy, with the potential to significantly improve outcomes for cancer patients. This research shows how ctDNA can be used to guide precision therapy, identify specific genetic changes in tumors, and tailor treatments to that specific mutation. This development can greatly reduce the need for invasive biopsies because in many brain and lung tumors biopsy is very difficult and sometimes impossible. This is a very big discovery that brings a very bright future in the field of oncology. 💡 Why is it important: Using ctDNA, oncologists can investigate tumor dynamics in a short amount of time, providing a non-invasive yet highly effective way to adjust treatments as the disease evolves. This approach not only targets the cancer more effectively, but also minimizes unnecessary treatments, reduces side effects, and improves patients' quality of life. 🔗 Do you want to know more about this transformative research? Read the full text of the article here: [https://lnkd.in/d56uzShG] How do you see the role of ctDNA in personalized cancer treatments? 🔬 #CancerResearch #Oncology #PrecisionMedicine #GastrointestinalCancer #TargetedTherapy #ctDNA #MedicalInnovation #research #researchdevelopment

Today, I was researching cancer and potential therapies that could be developed and found an interesting review article written by Jovanka Gencel-Augusto, Ph.D., Trever Bivona and Wei Wu. It focuses on research about long non-coding RNAs in lung cancer.🧫   Before reading about the findings, it is crucial to define what lncRNAs are, as mentioned in the article they are "non-protein coding molecules longer than 200 nucleotides. They play essential roles in normal cell function and development, and can contribute to diseases such as cancer when dysregulated."   Key facts from the review include that lncRNAs have highly context-specific functions, making detailed in vivo studies crucial to understanding their roles in physiological processes. They are very stable molecules present in the systemic circulation. And their resistance to degradation by nucleases for example, is attributed to factors such as their secondary structures, transport within exosomes, and stabilizing post-translational modifications. In therapeutic approaches, the way in which lncRNAs operate include inhibiting oncogenic lncRNAs or restoring the function of tumor-suppressive lncRNAs.   Additionally, future research could be developed on how lncRNAs influence immunotherapy responses because this area remains largely unexplored. From my perspective, I would use aptamers to target peptides encoded by lncRNAs and measure the differences on the inhibition of important genes associated with tumor growth from various malignancies. Moreover, it is also possible to make a comprehensive study of their role in signaling pathways and the interactome between coding and non-coding molecules, these findings could significantly enhance our understanding of this topic, benefiting the scientific community. I would highly recommend reading the article if you are interested in this field: https://lnkd.in/ewKPQTWb #lncRNAs #cancer #therapy #cancertherapy #lungcancer #pathways #molecules #regulation #cells

📢 New Test Could Reduce Bladder Cancer Checks   📊 A new study suggests that a test analysing urinary DNA (utDNA) could cut down the number of cystoscopies needed for bladder cancer patients. The test detects cancer recurrences with high sensitivity and often spots them earlier than traditional cystoscopy.   📉 Over two years, researchers from the Danish Cancer Institute, Oslo University Hospital and University of Oslo followed patients with repeated utDNA tests. This method provided detailed data, revealing that utDNA could identify recurrences in 91% of cases, and that almost half of all recurrences were detected earlier with utDNA than with cystoscopy. The test also showed potential to reduce the number of cystoscopies by 55%, benefiting 80% of patients. Professor Per Guldberg, one of the researchers behind the study, says:   💬 ”Cystoscopy is not only uncomfortable for patients but also costly for healthcare systems. By adopting this urine-based test, we can provide a more patient-friendly, cost-effective alternative that enhances the quality of care.”   The study - published in Molecular Oncology - highlights utDNA's high sensitivity, which meets European standards and aligns with patient preferences for noninvasive methods. While promising, more research is needed to confirm these findings in larger groups.   In summary, the BladMetrix utDNA test could improve bladder cancer monitoring by detecting recurrences early and reducing the need for invasive procedures. #cancer #cancerresearch #science #bladdercancer

In the early 2000s, the FDA approved the first liquid biopsy test to monitor cancer in people with advanced breast cancer, colorectal cancer, and prostate cancer. In 2016, the FDA approved another liquid biopsy test that detects specific mutations, or changes, in the DNA from tumor cells circulating in the blood of people with NSCLC. And recently in 2021, two other liquid biopsy tests were approved by the FDA to detect mutations in the DNA from tumor cells in the blood. As the demand for non-invasive diagnostic procedures grows, the liquid biopsy market is anticipated to grow at a CAGR of 15-20% over the next 5 years according to MedTech Dive and expand in areas outside of cancer such as Alzheimer’s disease. Meridian’s Liquid Biopsy qPCR Mixes are ultra-sensitive and can accurately detect single-digit copy numbers of targets such as ctDNA. In addition, the mixes are highly inhibitor tolerant and are designed to perform with crude blood, urine or stool samples, removing the need for DNA or RNA extraction. If extraction is needed, these mixes provide a level of sensitivity that is superior to anything available. To learn more, visit: https://ow.ly/h1XV50T79jp #moleculardiagnostics #liquidbiopsy #cancermarkers #biomarkers

💡Revolutionizing #BreastCancerResearch with Dr. Birgit Schilling 💡 Step into the realm of breast cancer research as Dr. Schilling introduces a novel FFPE-deparaffinization protocol combined with #ZenoSWATH #DIA assays. The quantitation of up to 6,000 proteins unveils significant down-regulation in ECM microenvironment proteins, providing insights into breast cancer progression. Discover Dr. Schilling's findings pointing towards potential therapeutic strategies. Watch the #ExtraordinaryScience here 👇👇👇👇 #ZenoTOF #massspectrometry #LifeScienceResearch #Proteomics